DNMT1 and atherosclerosis: Because administration of 5-Aza-dc attenuates atherosclerosis in Ldlr−/− mice [55], it is tempting to speculate that a combined regimen consisting of a DNMT inhibitor and a SIRT6 activator could be considered a novel therapeutic solution for patients with CHD.